Nima Farzan Sells 2,625 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Nima Farzan sold 2,625 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director directly owned 9,767 shares of the company’s stock, valued at approximately $104,799.91. This represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Stock Up 0.7%

KROS stock opened at $10.07 on Wednesday. The firm has a market cap of $199.29 million, a PE ratio of -3.35 and a beta of 0.94. The business has a 50 day moving average of $11.30 and a 200-day moving average of $15.05. Keros Therapeutics, Inc. has a 12-month low of $9.79 and a 12-month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. The business had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.93 million. On average, research analysts expect that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently made changes to their positions in KROS. Western Standard LLC lifted its position in shares of Keros Therapeutics by 42.7% during the third quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after acquiring an additional 654,989 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Keros Therapeutics by 282.5% during the fourth quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock worth $12,047,000 after acquiring an additional 436,986 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Keros Therapeutics during the second quarter worth $4,251,000. Caption Management LLC lifted its position in shares of Keros Therapeutics by 114.1% during the second quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after acquiring an additional 291,997 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its position in shares of Keros Therapeutics by 683.7% in the third quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock worth $4,795,000 after buying an additional 264,445 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on KROS shares. Weiss Ratings lowered Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, Wells Fargo & Company reduced their price objective on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $20.40.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.